Dual Bronchodilator Therapy: A Review
Inhaled bronchodilators with or without inhaled steroids (IGCs) are the mainstay of pharmacological treatment for stable obstructive airway diseases, including beta2-agonists and muscarinic antagonists. Long-acting muscarinic antagonist bronchodilators (LAMA) and long-acting β2-agonists (LABA) are the treatment of choice for moderate to severe chronic obstructive pulmonary disease (COPD). Also some studies have demonstrated the benefit of LAMA in the treatment of difficult-to-control asthma and the potential use in asthma-COPD overlap (ACO). Control of airway tone in health and disease states, cholinergic and adrenergic receptors, signaling, molecular biology of mediators, and airway muscle contraction / relaxation mechanisms are reviewed concisely and as they may be handled pharmacologically. Subsequently, the evidence of the role of the LABA / LAMA combination in the aforementioned entities, their complementary mechanisms of action and other alternative mechanisms of action as well as potential deleterious effects is discussed.
View Volume: http://bp.bookpi.org/index.php/bpi/catalog/book/135